CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market on Track for Major Expansion by 2034, According to DelveInsight | Eli Lilly and Company, Gilead Sciences, Novartis, Autolus Therapeutics

The Key CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Companies in the market include - Gilead Sciences, Novartis, Autolus Therapeutics, Cellectis, Guangzhou Bio-gene Technology, Eastern Cooperative, Beam Therapeutics Inc., Wugen, Inc., Eli Lilly and Company, Autolus Limited, Amgen Research (Munich) GmbH, Juventas Cell Therapy, Kiadis Pharma, Chongqing Precision Biotech, Takara Bio Inc., Bristol-Myers Squibb, Orca Biosystems, Inc., and others.

DelveInsight's "CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia, historical and forecasted epidemiology as well as the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Forecast [https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Report:

*
The CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market size was valued ~USD 200 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In March 2024, Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi Registered (lisocabtagene maraleucel; liso-cel), a CD19-targeted CAR T cell therapy, to treat adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two prior therapies, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This approval is based on response rate and duration, with continued approval potentially dependent on further confirmation of clinical benefits in ongoing trials.

*
In the 7MM, the United States had the largest market size in 2021, amounting to about USD 55 million.

*
In September 2023, Beam Therapeutics initiated treatment of the first patient with BEAM-201 in august, an investigational allogeneic CAR-T cell therapy edited using quadruplex technology. BEAM-201 is currently undergoing Phase I/II clinical trials aimed at treating relapsed/refractory CAR T-Cell Therapy For Acute Lymphoblastic Leukemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL), a serious condition impacting both children and adults.

*
While most clinical studies use autologous CAR-T cells for treating B-ALL, the use of allogeneic CAR-T cells has also been reported in a limited number of clinical studies. Key players like Precision Biosciences (PBCAR0191), Cellectis (UCART22), Wugen (WU-CART-007), and Cellectis/Servier/Allogene (UCART19) are currently testing their allogeneic products.

*
In 2023, the United States recorded around 6,800 incident cases of Acute Lymphoblastic Leukemia, with numbers expected to rise over the forecast period.

*
Within the EU4 and the UK, Germany reported the highest incidence of Acute Lymphoblastic Leukemia cases, whereas Spain had the lowest number of cases.

*
In 2023 in the U.S., gender-specific cases showed approximately 3,800 cases among males and 3,000 cases among females.

*
In the U.S., type-specific cases of Acute Lymphoblastic Leukemia in 2023 showed that B-Acute Lymphoblastic Leukemia represented about 85% of cases, while T-Acute Lymphoblastic Leukemia accounted for approximately 15%.

*
Key CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Companies: Gilead Sciences, Novartis, Autolus Therapeutics, Cellectis, Guangzhou Bio-gene Technology, Eastern Cooperative, Beam Therapeutics Inc., Wugen, Inc., Eli Lilly and Company, Autolus Limited, Amgen Research (Munich) GmbH, Juventas Cell Therapy, Kiadis Pharma, Chongqing Precision Biotech, Takara Bio Inc., Bristol-Myers Squibb, Orca Biosystems, Inc., and others

*
Key CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Therapies: TECARTUS (brexucabtagene autoleucel), KYMRIAH (tisagenlecleucel), Obecabtagene autoleucel (obe-cel), UCART22, CD7 CAR-T, Daratumumab, BEAM-201, WU-CART-007, LY3039478, AUTO3 (CD19/22 CAR T cells, Daratumumab, Blinatumomab (MT103), HY004, ATIR, pCAR-19B cells, TBI-1501, Apixaban, Orca-T, and others

*
The CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CAR T-Cell Therapy For Acute Lymphoblastic Leukemia pipeline products will significantly revolutionize the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market dynamics.

CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Overview

CAR T-cell therapy for Acute Lymphoblastic Leukemia (ALL) is a groundbreaking form of immunotherapy that leverages the body's own immune system to fight cancer. This therapy involves modifying a patient's T cells, a type of white blood cell, to target and kill leukemia cells.

Get a Free sample for the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market [https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Epidemiology Segmentation:

The CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market report proffers epidemiological analysis for the study period 2002-2034 in the 7MM segmented into:

*
Total Prevalence of CAR T-Cell Therapy For Acute Lymphoblastic Leukemia

*
Prevalent Cases of CAR T-Cell Therapy For Acute Lymphoblastic Leukemia by severity

*
Gender-specific Prevalence of CAR T-Cell Therapy For Acute Lymphoblastic Leukemia

*
Genetic Mutation-specific Cases of CAR T-Cell Therapy For Acute Lymphoblastic Leukemia

Download the report to understand which factors are driving CAR T-Cell Therapy For Acute Lymphoblastic Leukemia epidemiology trends @ CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Epidemiology Forecast [https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market or expected to get launched during the study period. The analysis covers CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Therapies and Key Companies

*
TECARTUS (brexucabtagene autoleucel): Gilead Sciences

*
KYMRIAH (tisagenlecleucel): Novartis

*
Obecabtagene autoleucel (obe-cel): Autolus Therapeutics

*
UCART22: Cellectis

*
CD7 CAR-T: Guangzhou Bio-gene Technology

*
Daratumumab: Eastern Cooperative

*
BEAM-201: Beam Therapeutics Inc.

*
WU-CART-007: Wugen, Inc.

*
LY3039478: Eli Lilly and Company

*
AUTO3 (CD19/22 CAR T cells: Autolus Limited

*
Daratumumab: Janssen Research & Development

*
Blinatumomab (MT103): Amgen Research (Munich) GmbH

*
HY004: Juventas Cell Therapy

*
ATIR: Kiadis Pharma

*
pCAR-19B cells: Chongqing Precision Biotech

*
TBI-1501: Takara Bio Inc.

*
Apixaban: Bristol-Myers Squibb

*
Orca-T: Orca Biosystems, Inc.

Discover more about therapies set to grab major CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market share @ CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Treatment Landscape [https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Strengths

*
Premium-price CAR-T cell therapies with better clinical profile expected to drive the growth of TALL market.

*
Collaborative efforts among pediatric oncology centers and research institutions enhance data sharing, standardization of treatment protocols, and access to specialized care for pediatric patients with T-ALL, improving overall treatment outcomes.

CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Opportunities

*
Rising awareness of targeted therapies amongst the population expected to drive the uptake of therapies.

*
Frontline setting is still relatively untapped and can provide the lucrative opportunities.

Scope of the CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Companies: Gilead Sciences, Novartis, Autolus Therapeutics, Cellectis, Guangzhou Bio-gene Technology, Eastern Cooperative, Beam Therapeutics Inc., Wugen, Inc., Eli Lilly and Company, Autolus Limited, Amgen Research (Munich) GmbH, Juventas Cell Therapy, Kiadis Pharma, Chongqing Precision Biotech, Takara Bio Inc., Bristol-Myers Squibb, Orca Biosystems, Inc., and others

*
Key CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Therapies: TECARTUS (brexucabtagene autoleucel), KYMRIAH (tisagenlecleucel), Obecabtagene autoleucel (obe-cel), UCART22, CD7 CAR-T, Daratumumab, BEAM-201, WU-CART-007, LY3039478, AUTO3 (CD19/22 CAR T cells, Daratumumab, Blinatumomab (MT103), HY004, ATIR, pCAR-19B cells, TBI-1501, Apixaban, Orca-T, and others

*
CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Therapeutic Assessment: CAR T-Cell Therapy For Acute Lymphoblastic Leukemia current marketed and CAR T-Cell Therapy For Acute Lymphoblastic Leukemia emerging therapies

*
CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Dynamics: CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market drivers and CAR T-Cell Therapy For Acute Lymphoblastic Leukemia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Unmet Needs, KOL's views, Analyst's views, CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Access and Reimbursement

To know more about CAR T-Cell Therapy For Acute Lymphoblastic Leukemia companies working in the treatment market, visit @ CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Treatment Landscape [https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Report Introduction

2. Executive Summary for CAR T-Cell Therapy For Acute Lymphoblastic Leukemia

3. SWOT analysis of CAR T-Cell Therapy For Acute Lymphoblastic Leukemia

4. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Patient Share (%) Overview at a Glance

5. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Overview at a Glance

6. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Disease Background and Overview

7. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Epidemiology and Patient Population

8. Country-Specific Patient Population of CAR T-Cell Therapy For Acute Lymphoblastic Leukemia

9. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Current Treatment and Medical Practices

10. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Unmet Needs

11. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Emerging Therapies

12. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Outlook

13. Country-Wise CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Analysis (2020-2034)

14. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Access and Reimbursement of Therapies

15. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Drivers

16. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Market Barriers

17. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Appendix

18. CAR T-Cell Therapy For Acute Lymphoblastic Leukemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=car-tcell-therapy-for-acute-lymphoblastic-leukemia-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-eli-lilly-and-company-gilead-sciences-novartis-autolus-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.